Latest from NYU Langone Health

In an interview with NeurologyLive, Andrew S. Feigin, MD, details ongoing trials that aim to treat Huntington disease, including the notable SIGNAL trial. 
VTS-72 is a proprietary combination of fumarate and VTS-Aspirin believed to improve the pharmacokinetics of fumaric acid while improving flush, which is estimated to occur in up to 40% of patients on a fumarate agent.
Mia Minen, MD, MPH, sat down for an interview to discuss why behavioral therapies could be an effective and easily accessible treatment for posttraumatic headaches following events like concussions.
At the 2019 American Academy of Neurology Conference, Mia Minen, MD, MPH took the time to sit down and discuss the behavioral therapies associated with treating migraine.
At the 2019 American Academy of Neurology Annual Meeting, Mia Minen, MD, MPH, discussed the opportunities that the increasing number of mobile health users presents for migraine treatment.
Interest in advancing research in stroke therapeutics has historically come in fits and starts. Now with intravenous tPA and thrombectomy in regular use, experts are looking to get a step ahead of the damage.
The child neurology resident at NYU Langone spoke about ways for residents to identify and address impaired colleagues that suffer from depression and burnout.
Recommendations to health care professionals in the community who play a role in managing pediatric patients with multiple sclerosis and considerations for improving how the condition is managed.
SAP Partner Banner